Dosing & administration for migraine

Emgality comes in an easy-to-use pen for self-administration that can fit into your patient’s life^1,2

^aPatient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use and the respondents’ confidence in their ability to use the device.³

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Recommended dosing with no titration required^1a

^aThe Emgality Pen needle is 27 gauge x 1/2 inch.⁴

CGRP=calcitonin gene-related peptide.

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

How to administer Emgality

Preparation⁷

• Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
• Choose an area for injection (abdomen or thigh if self-injecting or buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within an area) each month
• Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps⁷

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Watch how to use the Emgality Pen

Prescribing Information

Patient Information

Instructions for Use

If you or your patients have any questions about Emgality, click the “Contact Lilly” button at the top of your screen, or call 1-833-EMGALITY (1-833-364-2548) to talk to a healthcare provider.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

How to locate and prescribe Emgality using the Electronic Media Record (EMR) system

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.